Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
Status:
Completed
Trial end date:
2021-01-22
Target enrollment:
Participant gender:
Summary
Despite its aggressiveness and high incidence, to date, no targeted therapies exist for the
treatment of triple negative breast cancer (TNBC). Emerging evidence suggests a crucial role
of tumor immunology on outcome for this entity. Checkpoint inhibitors like pembrolizumab,
which target immune cells within the tumor, might therefore have an important impact on
therapy response and outcome in these high risk patients. We propose a phase II study
exploring pathological complete response and the safety of the combination of pembrolizumab
and nab-paclitaxel as well as the combination of pembrolizumab with epirubicin and
cyclophosphamide in the neoadjuvant setting for women with early TNBC. After completion of
this study an extension will be determined.